ClinicalTrials.gg
Active, not recruitingNCT04259944Updated Sep 28, 2023

Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial

A Phase 2 interventional study of CAPOX and Capecitabine in Colon Cancer, sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing capecitabine in Colonic Neoplasms — 3 open to participants now, 7 under way, 3 of them phase 3. Capecitabine · Colonic Neoplasms.

Planned enrollment
12th of 48
140 · median 51
Started
2020
with 3 others
Phase 2
26 of 53
1 open now
Registered
47th of 53
by date
Lead sponsor
2 of 53
IFOM ETS - The AIRC Institute of Molecular Oncology

Among the 53 studies testing capecitabine in Colonic Neoplasms, this one is the 12th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2020, is one of 26 in phase 2, and was the 47th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

3 of the 53 studies testing capecitabine in Colonic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing capecitabine in Colonic Neoplasms, or all of them as a file.
02

Study summary

PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon cancer patients.

Read the detailed description

The LUNAR1 Test (Guardant Health, Redwood City, CA, USA) will be used for ctDNA determination. For the efficacy analysis, the PEGASUS cohort will be compared with a cohort of 420 patients from the TOSCA trial (NCT00646607) population matched 3:1 for all known prognostic phenotypes.

A post-surgical LB executed 2-4 weeks after surgery will guide a "Molecular Adjuvant" treatment as follows: i) ctDNA+ patients will receive CAPOX for 3 months; ii) ctDNA- patients will receive capecitabine (CAPE) for 6 months but will be retested after 1 cycle, and if found ctDNA+ will be switched to CAPOX treatment.

Immediately after the end of the "Molecular Adjuvant" treatment a further LB will be performed and instruct subsequent treatment. Positive patients (ctDNA+/+ and ctDNA-/+) will receive an up-scaled "Molecular Metastatic" systemic treatment for 6 months or until radiological progression or toxicity as follows: i) ctDNA+/+ patients will be treated with FOLFIRI; ii) ctDNA-/+ patients with CAPOX. These patients will be subjected to a LB after 3 months at the end of treatment and in case of positivity will be switched to FOLFIRI.

Patients experiencing ctDNA conversion to negative (ctDNA+/-) will receive a de-escalated treatment with CAPE for 3 months. 3 LB will be performed within 3 months and in case of positivity the patient will be switched to FOLFIRI. Patients with ctDNA-/- will be subjected to an interventional follow-up comprising 2 further LB and in case of positivity they will be switched to CAPOX treatment. PEGASUS is piggybacked to AlfaOmega (NCT04120935), a Master Observational Protocol that will follow patients from diagnosis to 5 years or recurrence/death (whichever comes first), collecting clinical data, radio-images and biological samples. AlfaOmega provides a clinical and logistic ecosystem for the seamless integration of PEGASUS clinical results with the biological underpinning of colon cancer.

03

Conditions studied

  • Colon Cancer

Keywords

  • liquid biopsy
  • colon cancer
  • adjuvant treatment
  • ctDNA
  • colorectal cancer
  • CAPOX
  • FOLFIRI
  • CAPE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Pegasus trial written .
  • Age ≥ 18 years.
  • confirmed diagnosis of operable stage III or T4N0 stage II colon cancer located 12 cm from the anal verge by endoscopy and above the peritoneal reflection at surgery.
  • Availability of plasma collected prior to surgery.
  • Availability of the original FFPE tumor tissue.
  • Acceptance to undergo at least all the interventional liquid .
  • performance status 0-1.
  • Normal organ functions. (as defined in section 9.3)
  • Women with should complete a pregnancy test and be willing to use highly effective methods.

Exclusion Criteria:- Patients having a MSI-H/MMRd tumor are excluded from the study (done according to standard clinical practice).

  • History of another neoplastic disease, unless in remission for ≥ 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  • Had an incomplete diagnostic colonoscopy and/or polyps removal.
  • Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections). Patients should never have had any evidence of disease (including presence of tumor cells in the peritoneal lavage).
  • Current or recent treatment with another drug or participation in another investigational study
  • Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
  • Inadequate contraception (male or female patients) if of childbearing or procreational potential.
  • cardiovascular disease.
  • Acute or subacute intestinal occlusion or history of inflammatory bowel disease.
  • Pre-existing neuropathy > grade 1. Known grade 3 or 4 allergic reaction to any of the components of the treatment.
  • Has a known DPD (DihydroPyrimidine Dehydrogenase) deficiency.
  • Has a known Gilbert Syndrome or UGT1A1 homozygous *28/*28 germline variant.
  • Has a known history of (HIV). Note: No HIV testing is required.
  • Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  • Has a known history of active TB (Bacillus Tuberculosis).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Liquid Biopsy-Guided Adjuvant Treatment

    A post-surgical LB executed 2-4 weeks after surgery will guide a "Molecular Adjuvant" treatment: * ctDNA+ patients: CAPOX for 3 months * ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX. A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment: * ctDNA+/+ patients: up-scale to a "Molecular Metastatic" treatment with FOLFIRI for 6 months or until radiological progression or toxicity; * ctDNA-/+ patients: up-scale to a "Molecular Metastatic" treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI. * ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI. * ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment.

    Drug: CAPOX · Drug: Capecitabine · Drug: FOLFIRI

Interventions

  • DrugCAPOX

    DAY 1 * OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5% * CAPE 1000 mg/m2 administrated per os twice daily DAY 2-14 • CAPE 1000 mg/m2 os twice daily Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting.

  • DAY 1-14 • CAPE 1250 mg/m2 os twice daily Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting.

  • DrugFOLFIRI

    Day 1: * IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with * LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by * 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours. Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest.

06

What researchers measure

Primary outcomes

  1. Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection

    Cases that become positive at subsequent interventional LB or that experience radiological relapse

    Time frame: 2 years

Secondary outcomes

  1. Disease-Free Survival (DFS)

    Time frame: 2 & 3 years

  2. Overall Survival (OS)

    Time frame: 5 years

  3. Safety and tolerability according to CTCAE version 5.0

    Time frame: 2 years

  4. Assessment of QLQ-C30 and CR-29 EORTC questionnaires

    Time frame: 2 years

  5. Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free

    Time frame: 2 & 3 years

07

Study locations

11 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jul 2024, 48 months after the start.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 48 months is above that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2020
First posted
Feb 7, 2020
StartActual
Jun 16, 2020
Primary completionEst.
Jul 15, 2024
CompletionEst.
Oct 15, 2024
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04259944
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Collaborators
Guardant Health, Inc.
Responsible party
Sponsor
First posted
Feb 7, 2020
Start date
Jun 16, 2020
Primary completion
Jul 15, 2024 (estimated)
Completion
Oct 15, 2024 (estimated)
Last update
Sep 28, 2023

Study contacts

Sara Lonardi, MD
study chair · Istituto Oncologico Veneto IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion